Findings show that a non-invasive plasma multi-analyte panel can differentiate MSA from PD with clinically meaningful accuracy, and support prospective validation in larger cohorts.
Abstract
Multiple system atrophy (MSA) is a fatal, rapidly progressive atypical parkinsonism that responds poorly to Parkinson’s disease (PD) medications, and diagnostic precision remains a critical unmet need. Earlier, accurate diagnosis would give patients realistic prognostic expectations and enable timely clinical-trial enrollment. We sought plasma biomarkers discriminating MSA from PD. Plasma small RNA sequencing and extracellular vesicle proteomics in discovery cohorts, filtered by the Biomedical Oriented Logistic Dantzig (BOLD) selector, nominated two microRNAs (hsa-miR-520a-5p, hsa-miR-22-3p) and two proteins (LCAT, kallistatin). Candidates were quantified in independent cohorts by XENO-Q qPCR and sandwich ELISA, and multivariate logistic regression models including all pairwise interactions were trained (
N
= 65) and validated in an independently recruited testing cohort (MSA
N
= 22; PD
N
= 16). The combined microRNA–protein model achieved test-set AUC 0.813 (95% CI 0.654–0.971), with sensitivity 0.818 and specificity 0.750, outperforming microRNA-only (AUC 0.599) and protein-only (AUC 0.747) models and indicating complementary rather than redundant information. The markers converge on pathways of glycerophospholipid metabolism, cholesterol homeostasis, myelin integrity, and inflammatory regulation, consistent with the oligodendrocyte pathology central to MSA. These exploratory findings show that a non-invasive plasma multi-analyte panel can differentiate MSA from PD with clinically meaningful accuracy, and support prospective validation in larger cohorts.
An integrated multi-omics approach provides a robust framework for stage-specific PD monitoring and potential clinical deployment using multi-omics machine learning to identify biofluid-specific signatures and evaluated predictive performance.
A. Galal, Ahmed Moustafa, Mohamed Salama· npj Parkinson's Disease· 0 citations
This study defined the serum metabolomic signature of MSA and highlighted novel biomarkers, pathological mechanisms, and therapeutic targets deserving further validation.
Lin-Lin Wan, Zhao Chen, Na Wan et al.· Movement Disorders· 0 citations
Re-mining legacy mass spectrometry data for disease-relevant proteoforms, combined with pre-structured datasets, can accelerate evaluation of emerging blood-based biomarkers against neuropathological and molecular features of disease.
Charles C. Kim, Meghan Kerrisk Campbell, Maximilien Burq et al.· bioRxiv· 0 citations
Introduction Differentiating Alzheimer’s disease (AD) from both Parkinson’s disease (PD) and Lewy body dementia (DLB) is difficult due to their clinical similarities. Plasma biomarkers offer an alternative to neuroimaging and cerebrospinal fluid analysis; however, there are limitations with respect to differential diag...
U. Sandau, J. Wiedrick, Trevor J. McFarland et al.· Frontiers in Aging Neuroscie...· 0 citations
This large-scale proteome-wide study not only reveals significant proteomic changes preceding SLD diagnosis but also establishes GDF15 as both a promising preclinical biomarker and opening new avenues for early intervention in at-risk individuals.
NEMPI is interpreted as an abundance-based, neuroimmune-enriched, multibiofluid proteomic composite associated with broad cognitive-motor progression, not as a patient-level prediction tool, clinical threshold, cognition-specific biomarker, or causal mechanism.
Hao Wang, Guo-Qing Wu, D. Zhang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.